GV and Celgene-backed Armo BioSciences has filed to raise up to $86.3m in an offering that will fund clinical tests for its lead immuno-oncology candidate.
US-based immuno-oncology therapy developer Armo BioSciences, which is backed by pharmaceutical company Celgene and GV, the corporate venturing unit formerly known as Google Ventures, has filed for an $86.3m initial public offering.
Armo is working on drugs that will combat cancer by triggering the human body’s immune system to fight off tumours. They are designed to work in tandem with chemotherapies and checkpoint inhibitors as well as other immunotherapies.
The company will use the proceeds from the offering to…
